Kodiak Sciences (NASDAQ:KOD) Stock Rating Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Kodiak Sciences (NASDAQ:KOD) from a sell rating to a strong sell rating in a report issued on Saturday morning,Wall Street Zen reports.

Several other equities analysts also recently weighed in on KOD. Weiss Ratings reissued a “sell (d-)” rating on shares of Kodiak Sciences in a research report on Friday, July 10th. HC Wainwright reaffirmed a “buy” rating and set a $58.00 price objective on shares of Kodiak Sciences in a research note on Thursday, September 17th. JPMorgan Chase & Co. increased their price objective on Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Finally, The Goldman Sachs Group initiated coverage on Kodiak Sciences in a research report on Thursday. They set a “neutral” rating and a $36.00 price objective for the company. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $56.83.

Kodiak Sciences Price Performance

Shares of KOD opened at $32.35 on Friday. The firm has a 50 day simple moving average of $38.31 and a 200-day simple moving average of $37.26. Kodiak Sciences has a 1-year low of $10.94 and a 1-year high of $47.84. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -7.72 and a beta of 2.18.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.09). On average, equities analysts expect that Kodiak Sciences will post -3.89 earnings per share for the current fiscal year.

Institutional Trading of Kodiak Sciences

A number of hedge funds have recently added to or reduced their stakes in the business. V Square Quantitative Management LLC acquired a new position in shares of Kodiak Sciences during the 1st quarter valued at about $26,000. Westfuller Advisors LLC purchased a new position in shares of Kodiak Sciences during the 1st quarter worth about $26,000. EverSource Wealth Advisors LLC boosted its position in shares of Kodiak Sciences by 1,221.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock worth $28,000 after acquiring an additional 916 shares during the last quarter. KBC Group NV acquired a new stake in shares of Kodiak Sciences in the first quarter worth approximately $39,000. Finally, E Fund Management Co. Ltd. purchased a new stake in Kodiak Sciences in the second quarter valued at approximately $228,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Key Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Kodiak announced that it will report topline results on September 28 from the pivotal Phase 3 DAYBREAK study evaluating Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) in wet age-related macular degeneration. The readout is the primary near-term catalyst for KOD because successful results could support regulatory filings and materially improve the company’s commercial outlook. Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study
• Positive Sentiment: Market coverage highlights strong investor anticipation ahead of the DAYBREAK results, helping explain the recent surge in Kodiak’s shares. However, the move also raises the risk of a sharp reaction in either direction once the data are released. Kodiak Sciences Shares Surge Ahead of Phase 3 Readout
• Neutral Sentiment: Goldman Sachs initiated coverage with a Neutral rating and a $36 price target, implying moderate upside from the referenced price but signaling limited conviction before the clinical readout.
• Neutral Sentiment: Reported short-interest data showed zero shares sold short and a zero-day short-interest ratio, suggesting short covering is unlikely to be a meaningful driver of the recent move.
• Negative Sentiment: Some coverage argues Kodiak looks overvalued after its substantial rally. With the company still precommercial and previously reporting a quarterly EPS loss below consensus, disappointing DAYBREAK data could trigger significant downside. Kodiak Sciences Stock Looks Overvalued After Its 15x Run

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.